ClinicalTrials.gg
TerminatedNCT02229760Updated Sep 1, 2014

Effect of Steady State TPV/r on Intracellular Concentrations of Zidovudine and Carbovir for Patients With HIV

A Phase 1/2 interventional study of Tipranavir capsules and Ritonavir capsules in HIV Infections, sponsored by Boehringer Ingelheim. Terminated. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2014-09-01.

Sponsored by Boehringer Ingelheim · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
3
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing tipranavir in HIV Infections — none open to participants now, none under way, none of them phase 3. tipranavir · HIV Infections.

Enrollment
16th of 16
3 · median 151
Started
2006
with 1 other
Phase 1/2
Only one
of the 16
Registered
15th of 16
by date
Lead sponsor
11 of 16
Boehringer Ingelheim

Among the 16 studies testing tipranavir in HIV Infections, this one is the 16th largest by enrollment, is one of 2 that started in 2006, is the only one in phase 1/2, and was the 15th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

None of the 16 studies testing tipranavir in HIV Infections is open now. The open studies under HIV Infections, anywhere →

About tipranavir

tipranavir: first FDA approval 2005 (APTIVUS), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing tipranavir in HIV Infections as a file.
02

Study summary

To determine the effect of steady-state tipranavir 500 mg/ritonavir 200 mg (TPV/r) on intracellular concentrations of zidovudine triphosphate (ZDV-TP) and carbovir triphosphate (CBV-TP) and plasma viral load

03

Conditions studied

  • HIV Infections

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed before study participation
  2. Age >18 and \<60 years
  3. Female patients of who use a barrier method for at least 12 weeks before administration of study medication, during the study and for 28 days after administration of study medication has ended and who have a negative pregnancy test result
  4. Ability to swallow capsules without difficulty
  5. A (BMI) between 18 and 29 kg/m2
  6. Reasonable probability of completing the study
  7. A medical history, physical examination, and (ECG) before entering the study
  8. Agreement to abstain from alcohol from Day -2 to Day 24
  9. Agreement to abstain from ingesting grapefruit, grapefruit juice, Seville oranges or orange marmalade from Day -2 to Day 24
  10. Negative urine drug screen for drugs of abuse
  11. Documented -1 RNA load (by PCR) at screening of \<50 copies/mL for at least 3 months and on a stable ZDV or ABC regimen for at least 6 months. Acceptable documentation included laboratory data, letter, or verbal report from another provider noted in the patient's records
  12. All HIV-infected patients must be TPV naïve and must not have received a PI based regimen within 6 months of enrollment

Exclusion criteria

Exclusion Criteria:

  1. Female patients who had a positive serum pregnancy test during the screening period of Day -14 to Day -7 or who plan to breast-feed at time (Day 0 to 30 after TPV/r administration)
  2. Use of any other medicine within 30 days before Day 0
  3. Use of any known altering drug (i.e., phenothiazines, cimetidine, barbiturates, ketoconazole, fluconazole, rifampin, and herbal medications) within 30 days before Day 0. No antibiotics were permitted within 10 days before Day 0
  4. Ingestion of grapefruit, grapefruit juice, Seville oranges, or orange marmalade within 2 days of study entry (Day 0)
  5. Blood or plasma donations (>100 mL total) for research or altruistic reasons within 30 days before Day 0
  6. Seated systolic blood pressure either \<100 mm Hg or >150 mm Hg; resting heart rate either \<50 beats/minute or >90 beats/minute
  7. History of any illness (including malabsorption, irregular food intake, gastrointestinal intolerance, or allergy) that, in the opinion of the investigator, might confound the results of the study or pose additional risks in administering TPV/r
  8. Any acute illness within 2 weeks before Day 0
  9. Patients who were currently taking any over-the-counter medication within 7 days before Day 0, or who were currently taking any prescription drug that, in the opinion of the investigator (in consultation with the BI medical monitor or pharmacokineticist), would have interfered with either the absorption, distribution, or metabolism of TPV or ritonavir
  10. to TPV, ritonavir, or sulfonamide containing drugs, or antiretroviral drugs (marketed or experimental use as part of clinical research studies)
  11. Sulfonamide allergy, that in the opinion of the investigator, might confound the results of the study or pose additional risks in administering TPV/r
  12. Any laboratory value outside the normal reference range that is of clinical relevance at screening, according to the judgment of the investigator (i.e., and alanine aminotransferase levels 2.5-fold and 2.5-fold higher than the upper normal limit, respectively)
  13. Based on the compliance diary, the patient had less than 100% documented compliance for 7-14 days of background Antiretroviral (ARV) (i.e., ZDV and ABC) medications before Day -5 to 0 (visit 2)
  14. Use of any protease inhibitors (i.e., fosamprenavir, amprenavir, indinavir, saquinavir, lopinavir, ritonavir, atazanavir, and nelfinavir) within 6 months of enrollment
  15. Patients who are co-infected with active and/or C as determined by hepatitis serology.
  16. Use of any anti- medications (e.g. aspirin, dipyridamole, clopidogrel, or any over the counter anti-platelet medicine).
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    TPV/r (Tipranavir co-administered with low dose ritonavir)

    Drug: Tipranavir capsules · Drug: Ritonavir capsules

06

What researchers measure

Primary outcomes

  1. AUC0-12h (Area under curve) of intracellular ZDV-TP

    Time frame: Up to 12 hours after drug administration

  2. AUC0-12h (Area under curve) of carbovir-TP

    Time frame: Up to 12 hours after drug administration

Secondary outcomes

  1. Number of patients with clinical significant findings in vital sings

    Time frame: Up to 14 days after last drug administration

  2. Number of patients with clinical significant findings in physical examinations

    Time frame: Up to 14 days after last drug administration

  3. Number of patients with clinical significant findings in laboratory measurements

    Time frame: Up to 14 days after last drug administration

  4. Concentration of Zidovudine (ZDV) in plasma

    Time frame: Up to 14 days after drug administration

  5. Concentration of Abacavir (ABC) in plasma

    Time frame: Up to 14 days after drug administration

  6. Concentration of Tipranavir (TPV) in plasma

    Time frame: Up to 14 days after drug administration

  7. Concentration of ritonavir in plasma

    Time frame: Up to 14 days after drug administration

  8. Cmax (Maximum observed concentration)

    Time frame: Up to 14 days after drug administration

  9. Cp12h (Trough plasma concentration)

    Time frame: Up to 14 days after drug administration

  10. AUC0-12h (Area under curve)

    Time frame: Up to 14 days after drug administration

  11. Number of patients with adverse events

    Time frame: Up to 14 days after last drug adminnistration

  12. Percentage of patients with viral load (VL) <50

    Time frame: Up to 14 days after last drug adminnistration

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2006 and a primary completion of Sep 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2014
First posted
Sep 1, 2014
Start
Aug 2006
Primary completionActual
Sep 2007
Last update
Sep 1, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02229760
Responsible party
Sponsor
First posted
Sep 1, 2014
Start date
Aug 2006
Primary completion
Sep 2007
Last update
Sep 1, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tipranavir · Ritonavir

Start the discussion